(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 10.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.86%.
Adaptive Biotechnologies's revenue in 2024 is $174,502,000.On average, 4 Wall Street analysts forecast ADPT's revenue for 2024 to be $24,661,646,916, with the lowest ADPT revenue forecast at $24,271,562,963, and the highest ADPT revenue forecast at $25,149,583,437. On average, 5 Wall Street analysts forecast ADPT's revenue for 2025 to be $31,318,421,480, with the lowest ADPT revenue forecast at $29,901,032,940, and the highest ADPT revenue forecast at $32,642,083,766.
In 2026, ADPT is forecast to generate $38,217,469,568 in revenue, with the lowest revenue forecast at $36,915,765,162 and the highest revenue forecast at $39,602,289,709.